BioWorld

Jan. 28, 2010

View Archived Issues

Alnara Raises $35M Series B as PERTly Liprotamase Nears NDA

Alnara Pharmaceuticals Inc. is expected to announce Thursday morning the close of a $35 million Series B financing, which will support launch preparations for pancreatic enzyme replacement therapy (PERT) liprotamase. (BioWorld Today) Read More

Gilead Earnings Rise on Atripla, Truvada Sales

Read More

Profiling Methods Give Broader View in Basic, Clinical Studies

Read More

Government Work 'Easy Money'? Don't Bet Your R&D Budget on it

Read More

GenVec Raises $28M on Heels of Novartis Gene Therapy Deal

Read More

Spectrum Terminates Ozarelix BPH Program, Saving $40M

Read More

Clinic Roundup

Read More

Other News To Note

Read More